Reasearch progress of Zengshengping in the prevention and treatment of tumor
LIU Sida1 DENG Bo2 CHEN Dongmei2 JIA Liqun2
1.School of Clinical Medicine, Beijing University of Chinese Medicine (China-Japan Friendship Hospital), Beijing 100029, China;
2.Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China
Abstract：Zengshengping is a pure traditional Chinese medicine preparation which was developed by Cancer Institute of Chinese Academy of Medical Sciences. It is mainly used to block the precancerous lesion of the esophagus, improve the postoperative survival time of patients with esophageal and cardiac cancer, and gradually apply in the treatment of oral leukoplakia, reverse the chronic atrophic gastritis intestinal metaplasia and reduce the recurrence rate of postoperative of giant cell tumor of bone in extremities. The anti-tumor mechanism of Zengshengping is mainly related to regulation of Notch signaling pathway, promotion of tumor cell apoptosis, and inhibition of tumor cell proliferation. The active components of the medicinal components, such asfraxinellone, dictamnine, maackiain, obacunone and matrine in Sophorae Tonkinensis Radix Et Rhizoma and Dictamni Cortex, may play the main anti-tumor activity. At present, the relevant basic research of Zengshengping is still limited to exploring its influence on the expression of relevant molecules in tumor cells, and its role in tumor microenvironment remains to be further explained. At the same time, most of the relevant clinical studies have problems such as a small number of patients and a lack of rigor in the study design, so the multi-center, large-sample randomized controlled trials need to be further carried out.
刘思达1 邓博2 陈冬梅2 贾立群2. 增生平防治肿瘤的研究进展[J]. 中国医药导报, 2021, 18(2): 31-34.
LIU Sida1 DENG Bo2 CHEN Dongmei2 JIA Liqun2. Reasearch progress of Zengshengping in the prevention and treatment of tumor. 中国医药导报, 2021, 18(2): 31-34.
[1] 李虹义，刘端祺，张凤洲.增生平片治疗食管和胃疾患的临床多中心双盲对照观察[J].甘肃中医，1994（3）：25-26.
[2] 林培中，张金生，戎振鹏，等.食管癌前病变的药物阻断性治疗——抗癌乙片、维胺酯和核黄素三年和五年的阻断效果[J].中国医学科学院学报，1990（4）：235-245.
[3] 丁镇伟，高峰，林培中，等.食管癌前病变阻断性治疗的远期效果[J].中华肿瘤杂志，1999（4）：35-37.
[4] 增生平期临床协作组.增生平治疗食管上皮增生的Ⅲ期临床观察[J].中华肿瘤杂志，2000（6）：70-72.
[5] Song Y，Li L，Ou Y，et al. Identification of genomic alterations in oesophageal squamous cell cancer [J]. Nature，2014，509（7498）：91-95.
[6] Zhang Z，Wang Y，Yao R，et al. Cancer chemopreventive activity of a mixture of Chinese herbs （antitumor B） in mouse lung tumor models [J]. Oncogene，2004，23（21）：3841-3850.
[7] Lim KJ，Rajan K，Eberhart CG. Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling [J]. Anticancer Res，2012，32（7）：2689-2696.
[8] Sun Z，Guan X，Li N，et al. Chemoprevention of oral cancer in animal models，and effect on leukoplakias in human patients with ZengShengPing，a mixture of medicinal herbs [J]. Oral Oncol，2010，46（2）：105-110.
[9] Wang Y，Yao R，Gao S，et al. Chemopreventive effect of a mixture of Chinese Herbs （antitumor B） on chemically induced oral carcinogenesis [J]. Mol Carcinog，2013，52（1）：49-56.
[10] Guo Y，Ma Y，Hu X，et al. Long non-coding RNA CEBPA-AS1 correlates with poor prognosis and promotes tumorigenesis via CEBPA/Bcl2 in oral squamous cell carcinoma [J]. Cancer Biol Ther，2018，19（3）：205-213.
[11] Liu PF，Hu YC，Kang BH，et al. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma [J]. PLoS One，2017，12（7）：e0180620.
[12] Guan XB，Sun Z，Chen XX，et al. Inhibitory effects of Zengshengping fractions on DMBA-induced buccal pouch carcinogenesis in hamsters [J]. Chin Med J（Engl），2012，125（2）：332-337.
[13] 马丹，杨帆，廖专，等.中国早期食管癌筛查及内镜诊治专家共识意见（2014年，北京）[J].中国实用内科杂志，2015，35（4）：320-337.
[14] 陈志峰，侯浚，林培中，等.增生平阻断食管癌前病变的远期效应[J].实用医学杂志，2011，27（5）：866-867.
[15] 陈志峰，宋国慧，侯浚，等.食管癌及贲门癌术后中药增生平辅助治疗远期疗效分析[J].肿瘤研究与临床，2011， 23（12）：839-840.
[16] Wang TY，Chiu YW，Chen YT，et al. Malignant transformation of Taiwanese patients with oral leukoplakia： A nationwide population-based retrospective cohort study [J]. J Formos Med Assoc，2018，117（5）：374-380.
[17] Shearston K，Fateh B，Tai S，et al. Malignant transformation rate of oral leukoplakia in an Australian population [J]. J Oral Pathol Med，2019，48（7）：530-537.
[18] Lodi G，Franchini R，Warnakulasuriya S，et al. Interventions for treating oral leukoplakia to prevent oral cancer [J]. Cochrane Database Syst Rev，2016，7（7）：CD001829.
[19] 孙正，李宁，刘晓勇，等.增生平对口腔癌预防作用的实验和临床研究[J].北京口腔医学，2005（3）：168-171.
[20] 黄开明，李国成，陈清霞.增生平片治疗口腔白斑的疗效观察[J].中药材，2011，34（3）：495-497.
[21] 张广林，田书信，陈卫刚.胃复春片与增生平片治疗慢性萎缩性胃炎伴肠化临床疗效观察[J].现代医药卫生，2013，29（11）：1636-1637.
[22] Li D，Zhang J，Li Y，et al. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone [J]. World J Surg Oncol，2016，14：114.
[23] 郑闽前，胡清，汤琪春，等.术中局灶化疗辅以增生平片治疗四肢骨巨细胞瘤21例临床观察[J].河北医学，2003（8）：687-689.
[24] 路海滨，高洋，禹珊珊，等.山豆根多糖对Lewis肺癌小鼠抑瘤作用及免疫功能影响的实验研究[J].中药材，2018，41（6）：1459-1462.
[25] 曹洛云，李天娇，孟宪生，等.山豆根生物碱对DEN诱发肝癌大鼠的作用及机制研究[J].中国现代应用药学，2018，35（3）：370-374.
[26] 付海荣，庞毅，谭家华，等.山豆根治疗白血病作用机制的网络药理学研究[J].中国药房，2019，30（24）：3392-3398.
[27] Wang JY，Wang Z，Li MY，et al. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition，migration，invasion and proliferation by downregulating the HIF-1alpha and Slug signaling pathways [J]. Chem Biol Interact，2018，296：134-144.
[28] 郑彬，孙峰.黄药子醇提物对人胃癌细胞凋亡及FABP-5表达的影响[J].中国临床药理学与治疗学，2016，21（3）：252-258.
[29] 林艳，闫庆梓，李亚梅，等.夏枯草抗乳腺癌最佳组分筛选及其作用机制研究[J].中草药，2019，50（21）：5298-5306.
[30] Yin T，Yang G，Ma Y，et al. Developing an activity and absorption-based quality control platform for Chinese traditional medicine：Application to Zeng-Sheng-Ping（Antitumor B）[J]. J Ethnopharmacol，2015，172：195-201.
[31] Gao G，Law FC. Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA [J]. Drug Metab Dispos，2009，37（4）：884-891.
[32] Hui L，Chen Y. Tumor microenvironment：Sanctuary of the devil [J]. Cancer Lett，2015，368（1）：7-13.
2021, Vol. 18 
京公网安备 11010502046598号